Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.
Ball State University · with National Mango Board · NCT07045051
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 24
- US sites recruiting
- 1
- Study start
- March 26, 2025
- Record last updated
- July 1, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Large blood sugar and insulin increases after meals high in table sugar are related to risk for diabetes and heart disease. Additionally, large increases in blood sugar may also negatively impact vascular health. Previous research suggests that mango consumed in small quantities has blood sugar-lowering properties, but the evidence of this within larger, more realistic meals is limited. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to more favorable blood sugar, insulin, and vascular responses after eating breakfast meals. The investigators will compare the postprandial glycemic, insulinemic, and vascular response to low and high glycemic meals sweetened with either fresh mango or sucrose.
Being studied: Low-Glycemic Breakfast Containing Oats and Mango; High-Glycemic Breakfast Containing Cereal and Mango; Low-Glycemic Breakfast Containing Oats and Table Sugar; High-Glycemic Breakfast Containing Cereal and Table Sugar
Conditions: Healthy Participants
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 - 45 years.
- Body mass index between 18.5-35.0 kg/m2
- Not pregnant (females only)
- Not postmenopausal (females only).
- Not been diagnosed with cardiovascular disease.
- Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
- Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- Does not regularly take anti-inflammatory drugs (more than 2x week).
- Does not use glucose-lowering drugs (e.g., metformin)
- Does not use lipid-lowering drugs (e.g., statins)
- Does not use tobacco products or any illicit drugs.
- Does not have a pacemaker.
- Can consume mango, wheat, gluten, and milk.
- Can stay in a supine position in the dark for at least ten minutes.
Exclusion Criteria
- Not between the ages of 18-45
- Body mass index \< 18.5 kg/m2 or >35.0 kg/m2
- Pregnant (females only)
- Postmenopausal status (females only).
- Been diagnosed with cardiovascular disease.
- Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
- Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- Regularly take anti-inflammatory drugs (more than 2x week).
- Uses glucose-lowering drugs (e.g., metformin)
- Uses lipid-lowering drugs (e.g., statins)
- Uses tobacco products or any illicit drugs.
- Have a pacemaker.
- Allergic to mango, wheat, gluten, and/or milk.
- Unable to lay in supine position in the dark for at least ten minutes.
Recruiting US locations
Health Professions Building, Ball State University
Muncie, IN 47306
Site contact: Bryant Keirns, PhD · 765-285-8356 · bryant.keirns@bsu.edu
Study contacts (from the official record)
- Bryant Keirns, PhD · 765-285-8356 · bryant.keirns@bsu.edu
Similar studies in Indiana
All healthy volunteers studies in Indiana →- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Indianapolis, IN + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 18+